• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Royalty Pharma plc

    11/24/25 5:24:38 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RPRX alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001814876
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Royalty Pharma plc
    SEC File Number
    001-39329
    Address of Issuer
    110 East 59th Street
    New York
    NEW YORK
    10022
    Phone
    1-212-883-0200
    Name of Person for Whose Account the Securities are To Be Sold
    Terrance Coyne
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common Stock
    Goldman Sachs & Co. LLC
    200 West Street
    New York � NY � 10282
    695822765884.542724748911/24/2025
    NASD


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common Stock06/16/2020Acquired from issuer in private transactionThe IssuerCheckbox not checked6583206/16/2020None
    Common Stock02/12/2020Acquired as compensation -- Performance AwardsThe IssuerCheckbox not checked375002/12/2020Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    TPC RP EPA1 LLC
    110 East 59th Street
    New York � NY � 10022
    Common Stock11/17/2025187573898.44
    TPC RP 2021 LLC
    110 East 59th Street
    New York � NY � 10022
    Common Stock11/17/2025329201297459.5
    TPC RP EPA1 LLC
    110 East 59th Street
    New York � NY � 10022
    Common Stock11/17/2025187573491.75
    TPC RP 2021 LLC
    110 East 59th Street
    New York � NY � 10022
    Common Stock11/17/2025329241290475.93

    144: Remarks and Signature

    Remarks
    The sales of shares set forth herein are made in connection with a selling plan dated 8/8/2025, that is intended to comply with Rule 10b5-1(c). 65,832 shares to be sold by TPC RP 2021 LLC. 3,750 shares to be sold by TPC RP EPA1 LLC.
    Date of Notice
    11/24/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    08/08/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Goldman Sachs & Co. LLC on behalf of Terrance Coyne

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $RPRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RPRX

    DatePrice TargetRatingAnalyst
    1/30/2026$49.00Neutral → Buy
    UBS
    9/30/2025$42.00Buy
    Goldman
    5/16/2025$51.00Overweight
    Morgan Stanley
    6/3/2024$28.00Buy → Neutral
    UBS
    6/14/2022$47.00Buy
    UBS
    5/13/2022$53.00Sector Outperform
    Scotiabank
    4/27/2022$56.00Buy
    Goldman
    4/14/2022$50.00Neutral → Overweight
    JP Morgan
    More analyst ratings

    $RPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Research & Investments Urist Marshall sold $805,110 worth of Class A Ordinary Shares (20,000 units at $40.26) (SEC Form 4)

    4 - Royalty Pharma plc (0001802768) (Issuer)

    1/26/26 4:10:58 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & CFO Coyne Terrance P. sold $2,737,940 worth of Class A Ordinary Shares (69,582 units at $39.35) (SEC Form 4)

    4 - Royalty Pharma plc (0001802768) (Issuer)

    1/23/26 4:48:33 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Research & Investments Urist Marshall sold $790,346 worth of Class A Ordinary Shares (20,000 units at $39.52) (SEC Form 4)

    4 - Royalty Pharma plc (0001802768) (Issuer)

    1/20/26 5:00:25 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

    NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will report its fourth quarter and full year 2025 financial results on Wednesday, February 11, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the "Investors" page of the company's website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days. About Royalty Pharma Founded in 1996,

    1/20/26 4:15:00 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference

    Royalty funding market reached record high of $10 billion in 2025, powered by synthetic royaltiesRoyalty Pharma maintained industry leadership with announced transactions of $4.7 billion Multiple potential value-creating milestones expected across development-stage portfolio in 2026, including pivotal data readouts for daraxonrasib, litifilimab and pelacarsen NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today provided an update on its business performance, including recent key accomplishments. Pablo Legorreta, Royalty Pharma's Chief Executive Officer and Chairman of the Board, will discuss these updates on January 13, 2026 as part of a webcast presentation

    1/12/26 7:15:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

    Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva's anti-IL-15 candidate, TEV-‘408 TEV-‘408 is currently in Phase 1b for treatment of vitiligo and in Phase 2a for celiac diseaseFunding agreement supports Teva's Pivot to Growth strategy to accelerate its innovative pipeline and bring treatments to patients faster NEW YORK and PARSIPPANY, N.J., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a funding agreement of up to $500 million to acce

    1/11/26 5:15:00 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Royalty Pharma upgraded by UBS with a new price target

    UBS upgraded Royalty Pharma from Neutral to Buy and set a new price target of $49.00

    1/30/26 6:41:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Royalty Pharma with a new price target

    Goldman initiated coverage of Royalty Pharma with a rating of Buy and set a new price target of $42.00

    9/30/25 8:57:42 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on Royalty Pharma with a new price target

    Morgan Stanley initiated coverage of Royalty Pharma with a rating of Overweight and set a new price target of $51.00

    5/16/25 8:05:49 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPRX
    SEC Filings

    View All

    SEC Form 8-K filed by Royalty Pharma plc

    8-K - Royalty Pharma plc (0001802768) (Filer)

    12/22/25 4:13:15 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Royalty Pharma plc

    8-K - Royalty Pharma plc (0001802768) (Filer)

    12/22/25 11:37:20 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Royalty Pharma plc

    144 - Royalty Pharma plc (0001802768) (Subject)

    11/24/25 5:24:38 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPRX
    Financials

    Live finance-specific insights

    View All

    Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

    NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will report its fourth quarter and full year 2025 financial results on Wednesday, February 11, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the "Investors" page of the company's website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days. About Royalty Pharma Founded in 1996,

    1/20/26 4:15:00 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

    Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva's anti-IL-15 candidate, TEV-‘408 TEV-‘408 is currently in Phase 1b for treatment of vitiligo and in Phase 2a for celiac diseaseFunding agreement supports Teva's Pivot to Growth strategy to accelerate its innovative pipeline and bring treatments to patients faster NEW YORK and PARSIPPANY, N.J., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a funding agreement of up to $500 million to acce

    1/11/26 5:15:00 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

    Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva's anti-IL-15 candidate TEV-‘408TEV-‘408 is currently in Phase 1b for treatment of vitiligo and in Phase 2a for celiac diseaseFunding agreement supports Teva's Pivot to Growth strategy to accelerate its innovative pipeline and bring treatments to patients faster PARSIPPANY, N.J., and NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Royalty Pharma plc (NASDAQ:RPRX), today announced a funding agreement of up to $500 million to accel

    1/11/26 5:00:00 PM ET
    $RPRX
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Royalty Pharma plc

    SC 13G/A - Royalty Pharma plc (0001802768) (Subject)

    11/8/24 3:15:49 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Royalty Pharma plc

    SC 13D/A - Royalty Pharma plc (0001802768) (Subject)

    7/29/24 4:30:11 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Royalty Pharma plc (Amendment)

    SC 13G/A - Royalty Pharma plc (0001802768) (Subject)

    2/13/24 10:17:30 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RPRX
    Leadership Updates

    Live Leadership Updates

    View All

    Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director

    NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ: RPRX) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director. Dr. Love will continue to Chair the Nominating and Corporate Governance Committee. "I am delighted to welcome Ted to the key role of Lead Independent Director," said Pablo Legorreta, Chief Executive Officer of Royalty Pharma and Chairman of the Board. "Ted has extensive research-based biopharma experience gained over a long and successful career and currently serves as Immediate Past Chairman of the Biotechnology Innovation Organization's (BIO)

    9/29/25 8:15:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company's Board of Directors

    Strengthens Board of Directors with appointment of two new independent members, increasing independent representation to greater than 90%Underscores Royalty Pharma's commitment to enhanced corporate governance following acquisition of its external manager NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Carole Ho and Elizabeth (Bess) Weatherman to its Board of Directors, effective immediately. Carole Ho is Chief Medical Officer and Head of Development at Denali Therapeutics, a biopharmaceutical company focused on neurodegenerative diseases. Bess Weatherman is a Special Limited Partner of Warburg Pincus LLC, a leading global pr

    7/17/25 8:15:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma Appoints Vlad Coric, M.D. to the Company's Board of Directors

    NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Vlad Coric, M.D. to the company's Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. "I am excited to announce that we are strengthening our Board with the appointment of Vlad Coric," said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. "Vlad's entrepreneurial approach and outstanding leadership skills, hon

    4/8/25 4:15:00 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care